We examined the bone marrow of 45 patients with MDS at the gression. 10 These latter assays can be approached by Southern blot enrolled in an EORTC study and received low-dose Ara-C with or without growth factors according to the study protocol.
Introduction
Forty-five patients with myelodysplasia classified as RAEB or RAEBt according to FAB criteria 1 were enrolled in clinical Myelodysplastic syndromes (MDS) are a heterogeneous group trials in our institution and received either LD-AraC alone for of clonal hematopoietic disorders characterized by abnormali-14 days (2 × 10 mg/m 2 /day sc, days 1-14) or LD-AraC days ties in more than one hematopoietic lineage and which are 1-14 combined with rhGM-CSF (150 g/m 2 /day sc, E. colithen classified cytologically according to the French-Amerderived (Sandoz, Basel, Switzerland) or rhIL-3 (150 g/m 2 /day ican-British (FAB) classification. 1 Clinically, bone marrow failsc, E. coli-derived (Sandoz)) from day 8 to 21 according to ure predominates and approximately one-third of patients will the EORTC protocol 06903. Clinical inclusion criteria were: eventually develop acute leukemia. 2 Intensive chemotherapy (1) MDS with 5-30% blasts in the bone marrow aspirate; (2) or allogeneic bone marrow transplantation can be considered at least one of the following -transfusion-dependent anemia, in younger patients; 3,4 a widely used therapy applicable also severe thrombocytopenia (less than 50 × 10 9 /l), severe neutroto elderly patients is low-dose cytosine arabinoside (LDpenia (absolute neutrophil count less than 0.5 × 10 9 /l or AraC). 5 Treatment of MDS patients with a combination of LD-1 × 10 9 /l in the presence of a history of infections; and (3) age AraC and growth factors may have beneficial effects by between 15 and 80 years. Exclusion criteria were active infecenhancing bone marrow regeneration and by inducing protions, refractoriness to platelet support or previous treatment liferation of the leukemic cells, making them more sensitive within 2 weeks of study entry. Complete hematological to the cytotoxic action of LD-AraC.
6-8 Prognosis in MDS is response to treatment (CR) of patients was defined by norextremely variable depending on FAB type, bone marrow malization of all of the following parameters: white blood cell blast count, platelet and neutrophil counts, hemoglobin and count, hemoglobin (у6 mmol/l), platelet counts pancytopenia.
2 Chromosome abnormalities are found in 40-(Ͼ100 × 10 9 /l), and percentage of blast cells in the bone mar-70% of MDS patients. Patients with complex karyotypes and row (BM р5%). Moreover, cytological abnormalities had to abnormalities of chromosome 7 have a poor prognosis. 9 The normalize in BM for at least 4 weeks. Partial hematological finding of new or additional chromosomal abnormalities in response (PR) was defined if three of the following four parathe course of the disease is often associated with disease prometers had improved for at least 4 weeks: increase in hemoglobin level of 2.5 mmol/l, increase in platelet count of at least 50 × 10 9 /l, increase in granulocyte count of at least 1 × 10 22 An abnormal clone was and in another case a tcR-␤ gene rearrangement and at the defined by the presence of an identical structural defect in same time an IL-3 gene rearrangement could be demontwo or more mitoses or an identical numerical defect in three strated. Comparing the gene rearranged and not rearranged or more mitoses.
groups statistically, we found a trend to a better survival probability and a longer time until progression of the disease in patients without gene rearrangements ( Table 1 ). The blast count was not significantly different in the two groups
Southern blot analysis (SBA)
( Table 1) . A Kaplan-Meier analysis of patients with or without a clonal marker (either a cytogenetical or a gene SBA was performed whenever cells were available. DNA was rearrangement) at diagnosis of the disease did not show a sigprepared by standard methods, 23 then cut by restriction nificantly different survival probability, although cases without enzymes as recommended, the resulting fragments electroclonal markers showed a trend to longer survival ( Figure 1 ). phoretically separated on a 0.7% agarose gel, blotted on to Similar results could be found by analyzing the value of gene nitrocellulose and hybridized to several digoxygenated prorearrangements alone for predicting survival probability at bes: immunoglobulin JH (Ig-JH), 24 T cell receptor ␤-chain diagnosis (data not shown). (tcR-␤), 25 5Ј bcr, 26 GM-CSF, 27 G-CSF 28 or IL-3. 29 The reaction was developed by 5-bromo-4-chloro-3-indolylphosphate pToluidine salt (BCIP) and Nitroblue tetrazolium chloride (NBT) . Bands in addition to the germline band were interpreted as 'clonal bands' due to the clonal MDS cells in the Cytogenetics: Sixteen patients with MDS who had achi-BM aspirate.
Results in remission of MDS
eved hematological remission (nine in CR, seven in PR) could A clonal response to treatment was defined as 'complete be studied cytogenetically. Again, patients without a chromoresponse' if no cytogenetic aberration and no clonal bands somal aberration seemed to have a better survival probability by SBA as compared to examinations at diagnosis could be and a longer time until progression as compared to the group detected. A 'partial clonal remission' was defined if a with chromosomal aberrations (Table 2) , although the differreduction of cytogenetically abnormal clones could be seen ence was not significantly different. or if clonally rearranged cells vanished, but cytogenetically abnormal clones persisted or vice versa.
Southern blot analysis (SBA):
SBA could be performed in 12 patients with MDS who had achieved hematological Statistics remission. In five cases gene rearrangements were detectable: in three cases a GM-CSF gene rearrangement, in one case an Statistical comparison of data from patients was done by a Ig-JH and in another case a tcR-␤ gene rearrangement.
Mann-Whitney test for independent variables (U-test) or a
Patients without a gene rearrangement had a longer time until Kaplan-Meier estimation by means of a computer-driven statprogression (P = 0.042) as compared to the group with a gene istical program (Stasy, PIC Corp, Munich, Germany).
rearrangement. Survival, however, was not significantly different in the two groups (Table 2) .
Results

Results during evolution of MDS Results at diagnosis of MDS Clonality analysis can detect the involvement of more than one clone or clonal evolution in MDS:
The involvement of at least two different clones in the disease could be proven by cytogenetics and SBA in four of 27 patients studied at diagnosis or in the course of the disease. Patient 1 presented with Cytogenetics:
The complete karyotype could be evaluated in 23 of 30 patients at first diagnosis of MDS. Twelve of these an abnormal karyotype characterized by a 'missing Y chromosome' and an isochromosome 21. After chemotherapy a patients presented with a clonal, abnormal karyotype. Comparing these two groups statistically by a Mann-Whitney test clonal evolution of the cytogenetically abnormal cells could be demonstrated -two isochromosomes 21 could be we found that more patients without a chromosomal marker at diagnosis achieved a complete hematological remission;
detected. At the same time a bcr gene rearrangement could be detected which disappeared when the patient had prothey had a better survival probability (P = 0.028) and a longer gressed to AML. This means that at least two different abnormal clones (one with an isochromosome 21, one with a bcr gene rearrangement) were involved in the disease. Patient 2 had presented with a deletion of the long arm of chromosome 5. The patient had responded to chemotherapy, the detection could no longer be detected, but a rearrangement of the Ig-JH gene was seen which disappeared in the further course of the disease. This means that again two clones were involved in the disease: one with a deletion of chromosome 5 and one with an Ig-JH gene rearrangement. Patient 3 had presented with a bcr gene rearrangement which could no longer be detected after chemotherapy (Figure 2 ). At this time-point, however, a deletion of the long arm of chromsome 5 was seen, which disappeared in the further course of the disease. This means that at least two clones must have been involved in the disease -one with a bcr gene rearrangement and one with a deletion of the long arm of chromosome 5. Patient 4 had also presented with a bcr gene rearrangement which disappeared in the course of the disease. After therapy a monosomy of the chromosome 16 could be found cytogenetically, which means an involvement of a bcr gene rearranged clone and also a cytogenetically abnormal clone in the disease. blot and cytogenetical analyses might yield information about the involvement of more than one clone in the disease or a (35%) clonality analysis showed a change for the worse (in six cases rising proportions of aberrant metaphases were clonal evolution.
impaired; in two cases gene rearrangements originated (one tcR gene rearrangement and one GM-CSF gene rearrangement)). In four patients (17%) the involvement of
Correlation of results obtained by cytogenetics and SBA with response to treatment and survival
more than one clone in the disease could be shown (see also ' Results during evolution of MDS ' ). Figure 3 shows an example for clonality analysis in the In 30 of 45 (67%) patients clonal markers could be detected at diagnosis or in the course of the disease: 15 cytogenetical course of MDS. At diagnosis of MDS, BM cells of the patient shown were characterized by a clonal rearrangement of the markers, two rearrangements in the tcR-␤ gene, two GM-CSF gene rearrangements and one bcr gene rearrangement. Two GM-CSF gene. The additional band disappeared in the course of the disease while the patient responded to therapy and cases presented with a GM-CSF and also a tcR-␤ gene rearrangement, one case with a GM-CSF and a bcr gene became stronger again as the patient progressed to AML. These data show the value of clonality analyses to monitor rearrangement and one case with a tcR-␤ and an IL-3 gene rearrangement. In six cases a cytogenetical aberration and an the present status of the patient. Our data show that eight patients (31%) who had responded additional gene rearrangement could be demonstrated (four times an additional GM-CSF gene rearrangement, twice an hematologically also responded on a clonal level (Table 3) . Six patients (23%) who did not respond hematologically to additional Ig-JH gene rearrangement). Thirty cases could be studied for clonality in the course of the disease. In 23 of these therapy were also clonal 'nonresponders'. In three patients (12%), however, who had responded hematologically, no cases clonality analysis allowed a statement about predominating clones: in three cases (8%) the clonal situation remained clonal response could be detected which means the clonal marker could still be detected. In five patients (19%) who did more or less the same; in nine cases (39%) at least a transient reduction of clonal cells could be demonstrated (in six cases not clinically profit from therapy, clonal response could be detected which might also mean that in these patients more the percentage of aberrant metaphases improved; in three cases a GM-CSF gene rearrangement vanished). In eight cases than one clone is involved in the disease. In 52% of our patients clonal karyotype disorders at diagHematological nosis could be detected. In agreement with already published response data, 10,30-32 we could show that patients without clonal achieved chromosomal markers at diagnosis not only had a better survival probability but also a longer time until progression of
Yes No
the disease, and a better chance to achieve a complete hema-(n = 11) (n = 11) tological remission. MDS patients in remission who showed karyotype abnormalities also showed a trend to worse
Disappearance of chromosomal yes (n = 13) 8 5
prognosis.
or molecular marker no (n = 9) 3 6
Southern blot analyses are very useful in detecting clonal markers: X-chromosomal probes and also probes directed against T cell receptor, immunoglobulin, cytokine genes or bcr probes can be used to find clonal gene rearrangements at This means that clonality analysis is a useful tool to study diagnosis of AML and MDS, yielding a molecular marker for MDS-BM samples in order to find clonal markers and to monianalysis of residual disease and response to therapy. [17] [18] [19] [20] [21] tor the course of the disease, to study response to therapy, and Patients without gene rearrangements at diagnosis (60%) the involvement of more than one clone in the disease or showed a trend to better survival probability and a shorter clonal evolution, although the involvement of some clones time until progression. Moreover, not in every patient could might be overlooked.
our total panel of gene probes (tcR-␤, Ig-JH, bcr, GM-CSF, G-CSF, IL-3) be applied due to the low number of cells or DNA available, which means that clonal markers in these patients Discussion might have been underscored. Therefore, we could not estimate the prognostic value of the presence of single gene
Clonality in MDS means a worse prognosis
rearrangements for patients at this time-point, although it seems that the detection of any clonal marker might mean a MDS are clonal disorders characterized by preneoplastic worse prognosis for the patient (Figure 1 , Table 1 ). In clones, which result from a neoplastic transformation at the remission, MDS patients without a gene rearrangement had a level of the pluripotent stem cell.
11 Clonality has been demonlonger time until progression. No significant difference strated by the presence of a clonal cytogenetic abnormality in between the two groups could be evaluated with regard to a substantial proportion of MDS patients, 10,30 by PCR, 11,14,15 in survival. Summarizing our data, we can conclude, that situ hybridization, 12,16,31 isoenzyme or Southern blot analysis using X-chromosomal enzymes or probes.
13,17-20,32 Chromopatients who present with clonal markers -either a cyto-genetic marker or a clonal gene rearrangement -have a trend more, the possible involvement of more than one clone or a clonal shift in MDS can be detected in a greater majority of to worse prognosis (Figure 1) .
cases if SBA and cytogenetics are combined. Together with the background of possible clinical treatment plans these data can contribute interesting information about the biological
Clonality analysis is a good tool to study treatment response
behavior of MDS in the future. Consequently we think that clonality analyses should be performed in every MDS patient at diagnosis and in the course of the disease to gain inforWe used a combination of SBA and cytogenetics to study clonality, to measure treatment response and to estimate the mation about treatment response, the evolution of new clones or a clonal evolution/progress of the disease. Certainly new risk for progress.
In our study we show that cytogenetics and SBA are a useful probes (eg receptors for cytokines, tumor suppressor genes, oncogenes) have to be tested for their value in detecting clonal tool for studying treatment response. In 39% of the cases studied in the course of the disease, there was at least a transient cells or prognostically relevant subgroups. reduction of clonal cells, in 35% a clonal change for the worse could be seen, and in 8% the clonal situation remained more or less the same. A reduction of clonal cells might
